SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Praxis Precision Medicines, Inc. (PRAX) News

Follow Praxis Precision Medicines, Inc. (PRAX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol PRAX Asset equity Sector Markets 90 days 8 Last 300.65 Updated Nov 09, 2026, 12:13 PM UTC Open live news feed Open PRAX chart & news
M Praxis Precision Q3 Net Loss Widens to $94 Million on G&A Costs EQUITY | Nov 09, 2026, 12:13 PM UTC M Praxis Reports Q3 2026 Net Loss of $94.2 Million, Cash of $1.3 Billion Praxis reported a third-quarter net loss of $94.2 million, versus $73.9 million a year earlier, as general and administrative expenses increased. It ended September with $1.3 billion in cash, cash equivalents and marketa EQUITY | Nov 09, 2026, 12:03 PM UTC L Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: FMR LLC Filed on: November 5, 20 EQUITY | Nov 05, 2026, 06:25 PM UTC M Praxis Precision Medicines Q3 Results Scheduled for Nov. 9 Praxis Precision Medicines is scheduled to report Q3 results before the market opens on Nov. 9. Revenue is estimated at 0 USD, with EPS anticipated at (3.54) USD. EQUITY | Nov 02, 2026, 12:00 PM UTC L Praxis Precision Med Price Target Maintained With a $1201.00/Share by HC Wainwright & Co. Ratings actions from Benzinga NEWS | Sep 24, 2026, 10:36 AM UTC L Praxis Precision Med Price Target Maintained With a $582.00/Share by Needham Ratings actions from Benzinga NEWS | Sep 24, 2026, 09:55 AM UTC L Praxis Precision Medicines announces Nasdaq Rule 5635(c)(4) inducement grants Praxis Precision Medicines said its Board Compensation Committee approved inducement grants under Nasdaq Listing Rule 5635(c)(4) on September 1, 2026. EQUITY | Sep 03, 2026, 08:08 PM UTC L Praxis Precision Medicines announces Nasdaq Rule 5635(c)(4) inducement grants Praxis Precision Medicines, Inc. announced inducement grants under Nasdaq Listing Rule 5635(c)(4). EQUITY | Sep 03, 2026, 08:01 PM UTC H Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Motorola Solutions In c (NYSE: MSI ) rose sharply after the company reported better-than-expected second-quarter financial EARNINGS | Aug 06, 2026, 02:01 PM UTC L PRAX - Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results PRAX - Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results EARNINGS | Aug 06, 2026, 12:01 PM UTC L PRAX - Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 PRAX - Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 EARNINGS | Jul 30, 2026, 08:02 PM UTC M Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No Ne FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX ), a fully integrated, leading central nervous system (CNS) precision neuroscience REGULATION | Jun 29, 2026, 08:35 PM UTC H PRAX Seeks Faster Development Praxis Precision Medicines' seizure drug elsunersen receives Breakthrough Therapy Designation from the FDA after positive trial results EQUITY | Jun 22, 2026, 05:29 PM UTC H PRAX: FDA Grants Breakthrough Therapy Praxis Precision Medicines receives Breakthrough Therapy designation from FDA for Elsunersen to treat seizures associated with SCN2A development and epileptic encephalopathy REGULATION | Jun 22, 2026, 12:10 PM UTC H PRAX Receives FDA Breakthrough Praxis Precision Medicines receives FDA Breakthrough Therapy Designation for Elsunersen to treat seizures associated with SCN2A developmental and epileptic encephalopathy EQUITY | Jun 22, 2026, 12:02 PM UTC